-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Better Therapeutics (BTTX) and The Competition
Contrasting Better Therapeutics (BTTX) and The Competition
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it contrast to its peers? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.
Earnings & Valuation
This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.
Get Better Therapeutics alerts:| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.73 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 34.40 |
Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
7.5% of Better Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are held by institutional investors. 59.4% of Better Therapeutics shares are held by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.Risk and Volatility
Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.
Profitability
This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Analyst Ratings
This is a summary of current ratings for Better Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 278 | 0 | 2.65 |
Better Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. As a group, "Health services" companies have a potential upside of 160.81%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its peers.
Summary
Better Therapeutics beats its peers on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it contrast to its peers? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.
Better Treateutics(納斯達克代碼：BTTX-GET Rating)是“健康服務”行業的33家上市公司之一，但它與同行有何不同？我們將根據其估值、機構所有權、股息、收益、分析師建議、風險和盈利能力，將Better Treeutics與相關業務進行比較。
Earnings & Valuation
收益與估值
This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.
此表比較了Better Treateutics及其同行的總收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.73 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 34.40 |
| 總收入 | 淨收入 | 本益比 | |
| 更好的治療學 | $10,000.00 | -4,033萬元 | -0.73 |
| Better Treateutics的競爭對手 | 13.6億美元 | -9,847萬元 | 34.40 |
Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Better Treateutics的同行有更高的收入，但收入比Better Treateutics低。Better Treateutics的本益比低於同行，這表明它目前比行業內的其他公司更負擔得起。
Institutional & Insider Ownership
機構與內部人持股
Risk and Volatility
風險和波動性
Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.
Better Treateutics的貝塔係數為1.36，這意味著其股價的波動性比標準普爾500指數高36%。相比之下，Better Treateutics的貝塔係數為1.19，這意味著它們的平均股價波動性比標準普爾500指數高19%。
Profitability
盈利能力
This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.
此表比較了Better Treeutics及其同行的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 更好的治療學 | 不適用 | -200.73% | -114.68% |
| Better Treateutics的競爭對手 | -325.87% | -676.77% | -37.31% |
Analyst Ratings
分析師評級
This is a summary of current ratings for Better Therapeutics and its peers, as provided by MarketBeat.com.
這是由MarketBeat.com提供的Better Treateutics及其同行的當前評級摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 278 | 0 | 2.65 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 更好的治療學 | 0 | 0 | 2 | 0 | 3.00 |
| Better Treateutics的競爭對手 | 7 | 131 | 278 | 0 | 2.65 |
Better Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. As a group, "Health services" companies have a potential upside of 160.81%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its peers.
Better Treateutics目前的共識目標價為14.00美元，暗示潛在上漲845.95%。作為一個整體，“健康服務”公司有160.81%的潛在上行空間。鑑於Better Treeutics更高的共識評級和更高的可能上行空間，研究分析師顯然認為Better Treateutics比其同行更有利。
Summary
摘要
Better Therapeutics beats its peers on 8 of the 12 factors compared.
Better Treateutics在比較的12個因素中有8個超過了同行。
About Better Therapeutics
關於Better Treatetics
(Get Rating)
(獲取評級)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Better Treateutics，Inc.，一家處方數位治療公司，開發了一種認知行為療法，以解決心臟代謝性疾病的原因。該公司開發基於軟體的處方數位療法平臺，用於治療糖尿病、心臟病和其他心臟代謝疾病。其臨床開發候選藥物旨在治療心臟代謝性疾病，包括2型糖尿病、高血壓、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性腎臟疾病。該公司的主要候選產品是BT-001，這是一種治療2型糖尿病的研究PDT平臺。Better Treateutics，Inc.成立於2015年，總部位於加利福尼亞州舊金山。
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到更好的治療新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對Better Treateutics和相關公司的評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧